Description
PT0511 is a small molecule compound designed to target KRAS-mutated colorectal cancers. This agent is being developed specifically for patients with KRAS mutations or amplifications, which are present in approximately 40-50% of colorectal cancer cases. PT0511 represents a direct approach to targeting the historically "undruggable" KRAS protein in solid tumors including CRC.
Mechanism of Action
PT0511 appears to function as a KRAS inhibitor, though the specific mechanism of KRAS targeting has not been fully disclosed in available clinical data. The compound is designed to interfere with KRAS signaling pathways that drive tumor cell proliferation and survival in cancers harboring KRAS mutations or amplifications.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
| Administration | Oral |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.